c La sclerosi amiotropica laterale (ALS)

La sclerosi amiotropica laterale (ALS) è una sindrome neurodegenerativa di cui non esistono trattamenti per le guarigione. È stato condotto uno studio in vivo, su modello di topo NSC34 trattati con idrossifasudil e fasudil somministrati mediante l’acqua di abbeveraggio. Come parametri per valutare l’effetto farmacologico dei composti sono stati presi in considerazione la performance motoria, il tempo di sopravvivenza e le modifiche istologiche. Dai dati ottenuti è stato dimostrato che fasudil rallenta la progressione della malattia, aumenta il tempo di sopravvivenza e riduce la perdita neuronale mediante la soppressione dell’attività di ROCK. Questi risultati indicano che fasudil può essere un soppressore della degenerazione neuronale e dei sintomi della progressione relativi alla ALS e quindi può essere un potenziale farmaco per il trattamento di tale malattia (Takata et al, 2013).

BIBLIOGRAFIA

Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001; 286:64-70

Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science. 1997;275:1308–1311

Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem. 1996;271:20246–20249

Anonymous. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons. 2007

Arakawa K, Himeno H, Gondo T, Kirigaya J, Otomo F, Matsushita K, Nakahashi H, Shimizu S, Nitta M, Yano H, Endo M, Kimura K, Umemura S. Refractory vasospasms of the coronary arteries due to multiple factors: an autopsy case. Intern Med. 2014;53(9):963-7

Baptiste DC and Fehlings MG. Update on the treatment of spinal cord injury. Prog Brain Res. 2007;161:217-233

Begum N, Sandu OA, Ito M, Lohmann SM, Smolenski A. Active Rho kinase (ROK-alpha ) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. J Biol Chem. 2002;277:6214–6222

Birukova AA, Alekseeva E, Mikaelyan A, Birukov KG, FASEB J. 2007

Blankenhorn DH, Azen SP, Kramash DM, et al. Coronary angiographic changes with lovastatin therapy; the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993; 119:969- 976

Borchert M, Schöndorf T, Lübben G, Forst T, Pfützner A. Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function. Diabetes Technol Ther. 2007;9:410-420

Borrajo A, Rodriguez-Perez AI, Villar-Cheda B, Guerra MJ, Labandeira-Garcia JL. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP- induced dopaminergic cell death. Neuropharmacology. 2014 May 27;85C:1-8

Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Am. J. Respir. Crit. Care Med. 2000;161:1720

Chong CM, Shen M, Zhou ZY, Pan P, Hoi PM, Li S, Liang W, Ai N, Zhang LQ, Li CW, Yu H, Hou T, Lee SM. Discovery of a benzofuran derivative (MBPTA) as a novel ROCK inhibitor in protecting against MPP(+)-induced oxidative stress and cell death in SH-SY5Y cells. Free Radic Biol Med. 2014 Jun 25. pii: S0891-5849(14)00266-4.

Cockcroft DW, Davis BE. J. Allergy Clin. Immunol. 2006;118: 551

Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol. 2001;3:339–345

Cosentino F. L’endotelio: dalla flessibilità funzionale alla malattia cardiovascolare. Roma: Il Pensiero Scientifico Editore. 1998

Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000; 407:258-264

Cox DA, Vita JA, Treasure CB, et al. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation. 1989; 80:458-465

Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205–219

Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100:387– 390

Dimmeler S, Aicher A, Vasa, M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-397

Doublier S, Riganti C, Voena C, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, Bosia A. RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells. Mol Cancer Res. 2008 Oct;6(10):1607-20.

Drummond ES, Rodger J, Penrose M, Robertson D, Hu Y, Harvey AR. Effects of intravitreal injection of a Rho-GTPase inhibitor (BA-210), or CNTF combined with an analogue of cAMP, on the dendritic morphology of regenerating retinal ganglion cells. Restor Neurol Neurosci. 2014 Jan 1;32:391-402

Du J, Hannon GJ. Suppression of p160ROCK bypasses cell cycle arrest after Aurora-A/STK15 depletion. Proc Natl Acad Sci USA. 2004;101:8975–8980

Dubreuil CI, Winton MJ and McKerracher L. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J Cell Biol. 2003;162: 233-243

Ediger TL, Schulte NA, Murphy TJ, Toews ML. Transcription factor activation and mitogenic synergism in airway smooth muscle cells. Eur. Respir. J. 2003;21:759–769

Erwig LP, McPhilips KA, Wynes MW, Ivetic A, Ridley AJ, Henson PM. Differential regulation of phagosome maturation in macrophages and dendritic cells mediated by Rho GTPases and ezrin- radixin-moesin (ERM) proteins. Proc Natl Acad Sci USA. 2006;103:12825–12830

Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629–635

Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002; 105: 1756-1759

FDA talk paper. Bayer voluntarily withdraws Baycol on August 2001

Feng J, Ito M, Kureishi Y, Ichikawa K, Amano M, Isaka N, Okawa K, Iwamatsu A, Kaibuchi K, Hartshorne DJ, Nakano T. Rho-associated kinase of chicken gizzard smooth muscle. J Biol Chem. 1999;274:3744–3752

Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest. 2005;115:565–571

Fu P, Liu F, Su S, Wang W, Huang XR, Entman ML, Schwartz RJ, Wei L, Lan HY. Signaling Mechanism of Renal Fibrosis in Unilateral Ureteral Obstructive Kidney Disease in ROCK1 Knockout Mice. J Am Soc Nephrol. 2006;17:3105–3114

Fu X, Gong MC, Jia T, Somlyo AV, Somlyo AP. The effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-, GTPgammaS-, and phorbol ester-induced Ca2+-sensitization of smooth muscle. FEBS Lett. 1998;440:183–187

Fukumoto Y, Mohri M, Inokuchi K, Ito A, Hirakawa Y, Masumoto A, Hirooka Y, Takeshita A, Shimokawa H. Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol. 2007;49:117-121

Fukumoto Y, Shimokawa H. The role of Rho-kinase pathway on PAH. Nippon Rinsho. 2008; 66:2091-2096

Fukunaga T, Ikesugi K, Nishio M, Sugimoto M, Sasoh M, Hidaka H, Uji Y. The effect of the Rho- associated protein kinase inhibitor, HA-1077, in the rabbit ocular hypertension model induced by water loading.Curr Eye Res 2009;34:42-47

Furukawa N, Ongusaha P, Jahng WJ, Araki K, Choi CS, Kim HJ, Lee YH, Kaibuchi K, Kahn BB, Masuzaki H, Kim JK, Lee SW, Kim YB. Role of Rho-kinase in regulation of insulin action and glucose homeostasis. Cell Metab. 2005;2:119–129

Gerald Mizejewsky. Role of integrins in cancer: survey expression patterns. Molecular Medicine 1999; 44435.

Gosens R, Nelemans SA, Grootte Bromhaar MM, McKay S, Zaagsma J, Meurs H. Am. J. Respir. Cell. Mol. Biol. 2003;28:257

Gosens R, Schaafsma D, Meurs H, Zaagsma J, Nelemans SA. Role of Rhokinase in maintaining airway smooth muscle contractile phenotype. Eur. J. Pharmacol. 2004 B;483:71–78

Guilluy C, Eddahibi S, Agard C, Guignabert C, Izikki M, Tu L, Savale L, Humbert M, Fadel E, Adnot S, Loirand G, Pacaud P. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med. 2009; 179:1151-1158

Guo MF1, Meng J1, Li YH1, Yu JZ1, Liu CY1, Feng L1, Yang WF2, Li JL2, Feng QJ2, Xiao BG3, Ma CG. The inhibition of Rho kinase blocks cell migration and accumulation possibly by challenging inflammatory cytokines and chemokines on astrocytes. J Neurol Sci. 2014 May 27. pii: S0022- 510X(14)00324

Hall A. Small GTP-binding proteins and the regulation of the actin cytoskeleton. Annu Rev Cell Biol. 1994;10:31–54

Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 1988;241:42–52

Hirooka Y, Shimokawa H, Takeshita A. Rho-kinase, a potential therapeutic target for the treatment of hypertension. Drug News Perspect. 2004;17:523-527

Hirst SJ, Clin. Exp. Allergy. 2000;30:54

Hu E, Lee D. Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges. Expert Opin Ther Targets. 2005;9:715–736

Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43:13 – 24

Hyun Dong Je, Sun Young Park, Amy L Barbar and Uy Dong Sohn. The inhibition effects of rosiglitazone an agonist-indiced or spontaneous regulation of contractility. Arch Pharm Res. 2007;30:461-468

Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N, Narumiya S. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. Embo J. 1996;15:1885–1893

Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996; 15:1885–1893

Ishizaki T, Naito M, Fujisawa K, Maekawa M, Watanabe N, Saito Y, Narumiya S. p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett. 1997;404:118–124

Itagaki M, Takaguri A, Kano S, Kaneta S, Ichihara K, Satoh K. Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats. J Pharmacol Sci. 2009; 109:94- 101

J Matzno S, Yasuda S, Juman S, Yamamoto Y, Nagareya-Ishida N, Tazuya-Murayama K, Nakabayashi T, Matsuyama K. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. Pharm Pharmacol. 2005; 57:1475-1484

Jacobs M, Hayakawa K, Swenson L, Bellon S, Fleming M, Taslimi P, Doran J. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J Biol Chem. 2006;281:260-268

James SE, Burden H, Burgess R, Xie Y, Yang T, Massa SM, Longo FM, Lu Q. Anti-cancer drug induced neurotoxicity and identification of Rho pathway signaling modulators as potential neuroprotectants. Neurotoxicology. 2008;29:605-612

Jeffery PK, Thorax 53 (1998) 129

Jones P, Kafonek S, Laurora I, Hunninghake D.Comparative dose efficacy study of atorvastatin versussimvastatin, pravastatin, lovastatin, and fluvastatinin patients with hypercholesterolemia (the CURVES Study). Am J Cardiol. 1998; 81:582-587

Jugdutt BI, Idikio HA. Apoptosis and oncosis in acute coronary syndromes: assessment and implications. Mol Cell Biochem. 2005;270:177–200

Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999; 103:879-887

Kamiyama M, Utsunomiya K, Taniguchi K, Yokota T, Kurata H, Tajima N, Kondo K. Contribution of Rho A and Rho kinase to platelet-derived growth factor-BB-induced proliferation of vascular smooth muscle cells. J Atheroscler Thromb. 2003;10:117–123

Kandabashi T, Shimokawa H, Mukai Y, Matoba T, Kunihiro I, Morikawa K, Ito M, Takahashi S, Kaibuchi K, Takeshita A. Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol. 2002; 22:243–248

Kesherwani V, Tarang S, Barnes R, Agrawal SK. Fasudil reduces GFAP expression after hypoxic injury. Neurosci Lett. 2014 Jun 4;576C:45-50

Kobayashi M, Tanoue Y, Eto M, Baba H, Kimura S, Oda S, Taniguchi K, Tominaga R. A Rho-kinase inhibitor improves cardiac function after 24-hour heart preservation. J Thorac Cardiovasc Surg. 2008; 136:1586-1592

Kobayashi N, Takeshima H, Fukushima H, Koguchi W, Mamada Y, Hirata H, Machida Y, Shinoda M, Suzuki N, Yokotsuka F, Tabei K, Matsuoka H. Cardioprotective effects of pitavastatin on cardiac performance and remodeling in failing rat hearts. Am J Hypertens. 2009; 22:176-182

Kureishi Y, Kobayashi S, Amano M, Kimura K, Kanaide H, Nakano T, Kaibuchi K, Ito M. Rho- associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem. 1997;272:12257–12260

Lai A, Frishman WH Rho-kinase inhibition in the therapy of cardiovascular disease. Cardiol Rev. 2005;13:285-292

Lal Goel H., J. Li, S. Kogan, L. Languino. Integrins in prostate cancer progression. Endocrine-Related Cancer (2008) 15 657–664

Lamperti C, Naini AB, Lucchini V, Prelle A, Bresolin N, Moggio M, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol. 2005; 62:1709–1712

Largiadèr T, Eto M, Payeli SK, Greutert H, Viswambharan H, Lachat M, Zünd G, Yang Z, Tanner FC, Lüscher TF. Endothelial nitric oxide synthase gene transfer inhibits human smooth muscle cell migration via inhibition of Rho A. J Cardiovasc Pharmacol. 2008; 52:369-374

Laufs U, Endres M, Custodis F, Gertz K, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feed-back regulation of Rho GTPase gene transcription. Circulation. 2000; 102:3104-1031

Lee JH, Zheng Y, von Bornstadt D, Wei Y, Balcioglu A, et al. Selective ROCK2 Inhibition In Focal Cerebral Ischemia. Ann Clin Transl Neurol. 2014 Jan 1;1:2-14

Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491–501

Li Z, Dong X, Wang Z, Liu W, Deng N, Ding Y, Tang L, Hla T, Zeng R, Li L, Wu D. Regulation of PTEN by Rho small GTPases. Nat Cell Biol. 2005;7:399–404

Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors.J Cardiovasc Pharmacol. 2007;50:17-24

Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001; 104:365-372

Libby P. What have we learned about the biology of atherosclerosis?: the role of inflammation. Am J Cardiol. 2001; 88:3-6

Loirand G, Guérin P and Pacaud P. Rho Kinases in Cardiovascular Physiology and Pathophysiology Circ. Res. 2006; 98;322-334

Lord-Fontaine S, Yang F, Diep Q, Dergham P, Munzer S, Tremblay P, McKerracher L. Local inhibition of Rho signaling by cell-permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. J Neurotrauma. 2008;25:1309-1922

Lu Q, Longo FM, Zhou H, Massa SM, Chen YH. Signaling through Rho GTPase pathway as viable drug target. Curr Med Chem. 2009; 16:1355-1365

Mack CP, Somlyo AV, Hautmann M, Somlyo AP, Owens GK. Smooth muscle differentiation marker gene expression is regulated by RhoAmediated actin polymerization. J Biol Chem. 2001;276:341–347

Mallat Z, Gojova A, Sauzeau V, Brun V, Silvestre JS, Esposito B, Merval R, Groux H, Loirand G, Tedgui A. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res. 2003; 93:884–888

Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension. 2001; 38:1307–1310

Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation. 2002 Apr 2;105(13):1545-7

Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. Embo J. 1996;15:2208–2216

McElhinney B, Poynter ME, Shrivastava P, Hazen SL, Janssen-Heininger YM. Eosinophil peroxidase catalyzes JNK-mediated membrane blebbing in a Rho kinase-dependent manner. J Leukoc Biol. 2003;74:897–907

McKerracher L and Higuchi H. Targeting Rho to stimulate repair after spinal cord injury. J Neurotrauma. 2006;23:309-317

McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114:1417–1431

Miano JM. Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol. 2003; 35:577–593

Mills JC, Stone NL, Erhardt J, Pittman RN. Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. J Cell Biol. 1998;140:627–636

Mita S, Kobayashi N, Yoshida K, Nakano S, Matsuoka H. Cardioprotective mechanisms of Rho- kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J Hypertens. 2005; 23:87–96

Miyata K, Hitomi H, Guo P, Zhang GX, Kimura S, Kiyomoto H, Hosomi N, Kagami S, Kohno M, Nishiyama A. Possible involvement of Rho-kinase in aldosterone-induced vascular smooth muscle cell remodeling. Hypertens Res. 2008; 31:1407-1413

Morikage N, Kishi H, Sato M, Guo F, Shirao S, Yano T, Soma M, Hamano K, Esato K, Kobayashi S. Cholesterol primes vascular smooth muscle to induce Ca2 sensitization mediated by a sphingosylphosphorylcholine-Rho-kinase pathway: possible role for membrane raft. Circ Res. 2006;99:299–306

Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 2001;15:1062–1064

Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996;392:189–193

Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii N, et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res. 2007; 100:662–669

Nishio M, Fukunaga T, Sugimoto M, Ikesugi K, Sumi K, Hidaka H, Uji Y. The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes.Curr Eye Res. 2009;34:282-286

Nohria A, Grunert ME, Rikitake Y, Noma K, Prsic A, Ganz P, Liao JK, Creager MA. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res. 2006;99:1426-1432

Okumura N, Nakano S, Kay EP, Numata R, Ota A, Sowa Y, Sakai T, Ueno M, Kinoshita S, Koizumi N. Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing. Invest Ophthalmol Vis Sci. 2014 Jan 15;55(1):318-29.

Ongusaha PP, Kim HG, Boswell SA, Ridley AJ, Der CJ, Dotto GP, Kim YB, Aaronson SA, Lee SW. RhoE is a pro-survival p53 target gene that inhibits ROCK I-mediated apoptosis in response to genotoxic stress. Curr Biol. 2006;16:2466–2472

Otsuka T, Ibuki C, Suzuki T, Ishii K, Kodani E, Atarashi H, Kishida H, Takano T. Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris. Circ J. 2006;70:402-408

Otsuka T, Ibuki C, Suzuki T, Ishii K, Yoshida H, Kodani E, Kusama Y, Atarashi H, Kishida H, Takano T, Mizuno K. Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina. Coron Artery Dis. 2008;19:105-110

Pavone; Meccanismi periferici e centrali del dolore: Indagini comportamentali e nuovi approcci terapeutici in modelli animali; 2009

Pierno S, Didonna MP, Cippone V, De Luca A, Pisoni M, Frigeri A, et al. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. Br J Pharmacol. 2006; 149:909– 919

Pitts C. Data Safety Monitoring Board recommends continuation of BioAxone’s phase I/IIa clinical trial with its lead product Cethrin (R) (BA-210) in acute spinal cord injury 2005

Qi F, Ogawa K, Tokinaga Y, Uematsu N, Minonishi T, Hatano Y. Volatile anesthetics inhibit angiotensin II-induced vascular contraction by modulating myosin light chain phosphatase inhibiting protein, CPI-17 and regulatory subunit, MYPT1 phosphorylation. Anesth Analg. 2009;109:412-417

Ransom RF, Lam NG, Hallett MA, Atkinson SJ, Smoyer WE. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int. 2005;68:2473-2483

Riento K, Guasch RM, Garg R, Jin B, Ridley AJ. RhoE binds to ROCK I and inhibits downstream signaling. Mol Cell Biol. 2003;23:4219–4229

Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4:446–456

Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH, Liao JK. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/-haploinsufficient mice. Circulation. 2005;112:2959– 2965

Saito H, Minamiya Y, Saito S, Ogawa J, Leukoc J. Biol. 2002; 72:829

Satoh SI, Ikegaki I, Kawasaki K, Asano T, Shibuya M. Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies. Curr Vasc Pharmacol. 2014 Jun 13

Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun TH, Inoue M, Masatsugu K, Saito T, Fukunaga Y, Sakaguchi S, Arai H, Ohno N, Komeda M, Nakao K. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation. 2000; 101: 2030–2033

Schaafsma D, Bos IS, Zuidhof AB, Zaagsma J, Meurs H. 2006a. Inhalation of the Rho-kinase inhibitor Y-27632 reverses allergen-induced airway hyperresponsiveness after the early and late asthmatic reaction. Respir. Res. 2006 A; 7:121

Schaafsma D, Boterman M, de Jong AM, Hovens I, Penninks JM, Nelemans SA, Meurs H, Zaagsma J. Differential Rho-kinase dependency of full and partial muscarinic receptor agonists in airway smooth muscle contraction. Br. J. Pharmacol. 2006 B;147:737–743

Schaafsma D, Gosens R, Bos IS, Meurs H, Zaagsma J, Nelemans SA. Allergic sensitization enhances the contribution of Rho-kinase to airway smooth muscle contraction. Br. J. Pharmacol. 2004;143: 477–484

Schaafsma D, Gosens R, zaagsma J, Halayko A, Meurs H. Rho kinase inhibitors: A novel therapeutical intervention in asthma? Eur J of Pharma. 2008 B; 585:398-406

Schaafsma D, Roscioni SS, Meurs H, Schmidt M. Monomeric G-proteins as signal transducers in air way physiology and pathology. Cell signalling. 2008 A;20:1705-1714

Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, Breard J. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol. 2001;3:346–352

Segain JP, Raingeard de la Blétière D, Sauzeau V, Bourreille A, Hilaret G, Cario-Toumaniantz C, Pacaud P, Galmiche JP, Loirand G. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology. 2003;124:1180-1187

Shi J, Wei L. Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp. 2007; 55:61-75

Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M, Noda Y, Matsumura F, Taketo MM, Narumiya S. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol. 2005;168:941–953

Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science. 2004;306:990–995

Shirao S, Kashiwagi S, Sato M, Miwa S, Nakao F, Kurokawa T, Todoroki-Ikeda N, Mogami K, Mizukami Y, Kuriyama S, Haze K, Suzuki M, Kobayashi S. Sphingosylphosphorylcholine is a novel messenger for Rho-kinase-mediated Ca2+ sensitization in the bovine cerebral artery: unimportant role for protein kinase C. Circ Res. 2002;91:112–119

Song Y, Hoang BQ, Chang DD. ROCK-II-induced membrane blebbing and chromatin condensation require actin cytoskeleton. Exp Cell Res. 2002;278:45–52

Takata M(1), Tanaka H, Kimura M, Nagahara Y, Tanaka K, Kawasaki K, Seto M, Tsuruma K, Shimazawa M, Hara H. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol. 2013 Sep;170(2):341-51

Takeda N, Kondo M, Ito ., Ito Y, Shimokata K, Kume H. Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am. J. Respir. Cell Mol. Biol. 2006;35:722–729

Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers.Arch Ophthalmo. 2008;126:309-315

Tanihara, T. Inoue, T. Yamamoto, Y. Kuwayama, H. Abe, M. Araie. Phase 1 clinical trials of a